Modified vaccinia virus Ankara delivers a robust surrogate marker for immune monitoring to sarcoma cells even if cells are being exposed to chemotherapy and heat treatment

References

• Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999, 190: 1669–1782
   Google Scholar
• Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001, 61: 6451–6458
   Google Scholar
• Wolchok JD, Livingston PO. Vaccines for melanoma: Translating basic immunology into new therapies. Lancet Oncol 2001, 2: 205–211
   Google Scholar
• Marten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, et al. Allogeneic dendritic cells fused with tumor cells: Preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 2003, 14: 483–494
   Google Scholar
• Finn OJ. Cancer vaccines: Between the idea and the reality. Nat Rev Immunol 2003, 3: 630–641
   Google Scholar
• Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005, 5: 296–306
   Google Scholar
• Slingluff CL, Jr, Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. Clin Cancer Res 2006, 12: 2342 s–2345 s
   Google Scholar
• Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: A randomised phase 3 multicentre study. Lancet Oncol 2010, 11: 561–570
   Google Scholar
• Marcove RC, Southam CM, Levin A, Mike V, Huvos A. A clinical trial of autogenous vaccine in osteogenic sarcoma in patients under the age of 25. Surg Forum 1971, 22: 434–435
   Google Scholar
• Moss B. Genetically engineered pox viruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA. 1996, 93: 11341–11348
   Google Scholar
• Sutter G, Staib C. Vaccinia vectors as candidate vaccines: The development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 2003, 3: 263–271
   Google Scholar
• Drexler I, Antunes E, Schmitz M, Wolfel T, Huber C, Erfle V, et al. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: Induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res 1999, 59: 4955–4963
   Google Scholar
• Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, et al. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol 1998, 161: 6985–6992
   PubMed Web of Science ®Google Scholar
• Yee C, Gilbert MJ, Riddell SR, Brichard VG, Fefer A, Thompson JA, et al. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol 1996, 157: 4079–4086
   Google Scholar
• Di Nicola M, Carlo-Stella C, Mortarini R, Baldassari P, Guidetti A, Gallino GF, et al. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: A phase I trial in metastatic melanoma. Clin Cancer Res 2004, 10: 5381–5390
   Google Scholar
• Meyer RG, Britten CM, Siepmann U, Petzold B, Sagban TA, Lehr HA, et al. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother 2005, 54: 453–467
   Google Scholar
• Milani V, Frankenberger B, Heinz O, Brandl A, Ruhland S, Issels RD, et al. Melanoma-associated antigen tyrosinase but not Melan-A/MART-1 expression and presentation dissociate during the heat shock response. Int Immunol 2005, 17: 257–268
   Google Scholar
• Boulanger D, Baier R, Erfle V, Sutter G. Generation of recombinant fowlpox virus using the non-essential F11L orthologue as insertion site and a rapid transient selection strategy. J Virol Methods 2002, 106: 141–151
   Google Scholar
• Gasteiger G, Kastenmuller W, Ljapoci R, Sutter G, Drexler I. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol 2007, 81: 11925–11936
   Google Scholar
• Staib C, Drexler I, Ohlmann M, Wintersperger S, Erfle V, Sutter G. Transient host range selection for genetic engineering of modified vaccinia virus Ankara. Biotechniques 2000, 28: 1137–1142, 44–46, 48
   Google Scholar
• Hatzfeld-Charbonnier AS, Lasek A, Castera L, Gosset P, Velu T, Formstecher P, et al. Influence of heat stress on human monocyte-derived dendritic cell functions with immunotherapeutic potential for antitumor vaccines. J Leukoc Biol 2007, 81: 1179–1187
   Google Scholar
• Westermann AM, Jones EL, Schem BC, van der Steen-Banasik EM, Koper P, Mella O, et al. First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma. Cancer 2005, 104: 763–770
   Google Scholar
• Van Bree C, Beumer C, Rodermond HM, Haveman J, Bakker PJ. Effectiveness of 2′,2′difluorodeoxycytidine (gemcitabine) combined with hyperthermia in rat R-1 rhabdomyosarcoma in vitro and in vivo. Int J Hyperthermia 1999, 15: 549–556
   Google Scholar
• Miller RC, Richards M, Baird C, Martin S, Hall EJ. Interaction of hyperthermia and chemotherapy agents: Cell lethality and oncogenic potential. Int J Hyperthermia 1994, 10: 89–99
   Google Scholar
• Calderwood SK, Theriault JR, Gong J. How is the immune response affected by hyperthermia and heat shock proteins?. Int J Hyperthermia 2005, 21: 713–716
   Google Scholar
• Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res 2007, 39: 271–278
   Google Scholar
• Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, et al. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 2003, 171: 4893–4897
   Google Scholar
• Dillman R, Barth N, Selvan S, Beutel L, de Leon C, DePriest C, et al. Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas. Cancer Biother Radiopharm 2004, 19: 581–588
   Google Scholar
• Dillman RO, Wiemann M, Nayak SK, DeLeon C, Hood K, DePriest C. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: A randomized phase 2 trial of the cancer biotherapy research group. J Immunother 2003, 26: 367–373
   Google Scholar
• Mahvi DM, Shi FS, Yang NS, Weber S, Hank J, Albertini M, et al. Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: Report of a phase I/IB study. Hum Gene Ther 2002, 13: 1711–1721
   Google Scholar
• Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005, 23: 2004–2011
   Google Scholar
• Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 2001, 250: 462–475
   Google Scholar
• Mayr A, Stickl H, Muller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: Marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's translation from German)]. Zentralbl Bakteriol (B). 1978 Dec, 167: 375–390
   Google Scholar
• Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Sheperd D, Gilbert SC, et al. Recombinant modified vaccinia Ankara primes functionally activated CTL specific for melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 2005, 113: 159–166
   Google Scholar
• DiNicola M, Carlo-Stella C, Anichini A, Mortarini R, Guidetti A, Tragni G, et al. Clinical protocol. Immunization of patients with malignant melanoma with outologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: Phase I trial. Hum Gene Ther 2003, 14: 1347–1360
   Google Scholar